Viralgen is a specialized CDMO and a key player in the gene therapy supply chain, focusing solely on AAV vector manufacturing. It combines deep scientific expertise in AAV with substantial, dedicated production capacity to help biotech companies scale their therapies from research to commercialization. As a subsidiary of AskBio, it benefits from foundational IP and scientific backing while operating independently to serve a broad client base, boasting an impressive track record of regulatory submissions and batch production.
Rare Genetic DiseasesCentral Nervous System Diseases
Technology Platform
Proprietary Aava™ platform for end-to-end AAV vector process development, analytics, and scalable cGMP manufacturing, supported by data from 1500+ batches across 30+ serotypes.
Funding History
4
Total raised:$330M
Series B$120MNovo Holdings
Series B$120MNovo Holdings
Series A$40MColumbus Venture Partners
Series A$50MYsios Capital
Opportunities
The massive and growing global demand for high-quality, scalable AAV manufacturing presents a significant bottleneck that Viralgen's dedicated capacity and expertise are uniquely positioned to address.
Strategic collaborations with next-generation technology developers, like Apertura, allow Viralgen to stay at the forefront of innovation and capture value from advanced capsid platforms.
The continued trend of biopharma outsourcing complex biologics manufacturing further solidifies its market position.
Risk Factors
High concentration risk in the AAV gene therapy sector makes the company vulnerable to scientific, clinical, or regulatory setbacks affecting the entire modality.
Intense competition from both large, diversified CDMOs and new AAV-focused entrants could erode market share and pricing power.
Operational execution risk is paramount, as any significant quality failure at its large-scale facility could critically damage its reputation and client trust.
Competitive Landscape
Viralgen competes in the high-end AAV CDMO space against other specialized players like Thermo Fisher Scientific (Brammer Bio), Lonza, and Catalent, as well as the internal manufacturing capabilities of large pharma. Its key differentiators are its exclusive focus on AAV, its claimed largest dedicated capacity, and the proven track record of its proprietary Aava™ platform. The competitive landscape is intensifying as demand surges, pushing all players to expand and innovate.
